Health care stocks were falling hard this afternoon, with the NYSE Health Care Index sinking 1.1% while the SPDR Health Care Select Sector ETF (XLV) was down 1.2%.
The Nasdaq Biotechnology index also was dropping 1.6%.
In company news, Virios Therapeutics (VIRI) slumped more than 71% on Monday after the antiviral therapies company said its IMC-1 drug candidate did not produce a statistically significant improvement in symptoms over baseline levels in patients with fibromyalgia during phase 2b trial.
Syros Pharmaceuticals (SYRS) tumbled nearly 24% after the drug maker late Friday closed on its acquisition of Tyme Technologies (TYME), as well as wrapping up an oversubscribed $130 million private investment in a public equity transaction with new and existing shareholders, including founding investor Flagship Pioneering.
Valneva (VALN) slid 17% after the French biotech company late Friday said it was terminating its collaboration with privately held IDT Biologika to mass-produce Valneva's VLA2001 COVID-19 vaccine after the European Commission reduced its advance purchase order. Under terms of the companies' November 2021 partnership, Valneva will pay up to 36.2 million euros ($36.3 million) in cash to IDT to scrap the deal and will also contribute 4.5 million euros of in-kind services to the German drug manufacturer.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
